NemDx is creating a medical diagnostic platform to bring into context how proteins function and how biophysical characteristics and biochemical structures interact in disease in the areas of neurodegenerative disease and oncology.
The NemDx approach aims at revealing critical information on alternative splicing, post-translation modifications and conformation changes of proteins in patients with neurodegenerative diseases. As proof-of-concept, NemDx developed, the first of its kind, an approach to diagnose ALS in blood. The innovation arises from quantifying the change in functional activity of the protein TDP-43.
